HC Wainwright reissued their buy rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report released on Monday, AnalystRatings.com reports.
Several other analysts have also issued reports on the stock. ValuEngine upgraded shares of Genocea Biosciences from a hold rating to a buy rating in a report on Friday, November 1st. Zacks Investment Research lowered shares of Genocea Biosciences from a buy rating to a hold rating in a report on Tuesday, October 29th. Finally, Needham & Company LLC restated a buy rating and issued a $10.00 price objective on shares of Genocea Biosciences in a report on Thursday, October 24th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $12.94.
GNCA traded up $0.01 on Monday, hitting $2.25. The company had a trading volume of 241,400 shares, compared to its average volume of 297,488. The firm has a market cap of $56.48 million, a P/E ratio of -0.61 and a beta of 2.43. Genocea Biosciences has a 1 year low of $1.99 and a 1 year high of $11.28. The company’s fifty day moving average price is $2.60 and its 200 day moving average price is $3.16. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.45.
A number of institutional investors and hedge funds have recently modified their holdings of GNCA. Morgan Stanley purchased a new stake in Genocea Biosciences during the second quarter worth about $26,000. Cubist Systematic Strategies LLC purchased a new stake in Genocea Biosciences during the second quarter worth about $40,000. Wedbush Securities Inc. purchased a new stake in Genocea Biosciences during the second quarter worth about $43,000. Citadel Advisors LLC purchased a new stake in Genocea Biosciences during the second quarter worth about $68,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Genocea Biosciences during the second quarter worth about $84,000. Hedge funds and other institutional investors own 56.33% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.